Product Pathways - Growth Factors/Cytokines
Human Interleukin-8 (hIL-8) #8921
Recombinant human IL-8 (hIL-8) Ser28-Ser99 (Accession #NM_000584) was produced in E.coli at Cell Signaling Technology.
Recombinant hIL-8 does not have a Met on the amino terminus and has a calculated MW of 8,386. DTT-reduced and non-reduced protein migrate as 8 kDa polypeptides. The expected amino-terminal SAKEL of recombinant hIL-8 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-8. All lots are greater than 98% pure.
The bioactivity of recombinant hIL-8 was determined by upregulation of CD11b expression on primary human neutrophils. The ED50 of each lot is between 1-5 ng/ml.
The purity of recombinant hIL-8 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-8 and staining overnight with Coomassie Blue.
Less than 0.01 ng endotoxin/1 μg hIL-8.
With carrier:SC: A 0.22 μm filtered solution of 0.25 mg/ml hIL-8 in PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-8.LC: A 0.22 μm filtered solution of 0.33 mg/ml hIL-8 in PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-8.Carrier free:SF: A 0.22 μm filtered solution of 0.25 mg/ml hIL-8 in PBS, pH 7.2.LF: A 0.22 μm filtered solution of 0.33 mg/ml hIL-8 in PBS, pH 7.2.
The prototypical CXC chemokine, IL-8, is best known for effects on neutrophils, specifically its ability to act as a chemoattractant and activate degranulation and respiratory burst (1,2,3).IL-8 is produced by a number of cell types including monocytes, T cells, neutrophils, fibroblasts, endothelial cells, and others (1). In addition to its effects on neutrophils, IL-8 promotes angiogenesis, inhibits endothelial cell apoptosis, and promotes the proliferation of melanoma cells in an autocrine fashion (1). As a result, IL-8 may be a contributing factor to the development of certain cancers (1,2). There are two distinct receptors for IL-8, CXCR1 and CXCR2; both are G protein-coupled receptors (1). Ligand binding induces Ca2+ mobilization and activates the PI3K, PKC, Rho, and Rac pathways (1,3).
- Payne, A.S. and Cornelius, L.A. (2002) J Invest Dermatol 118, 915-22.
- Brat, D.J. et al. (2005) Neuro Oncol 7, 122-33.
- Mukaida, N. (2003) Am J Physiol Lung Cell Mol Physiol 284, L566-77.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.